Their study demonstrated that AIP was a stronger predictor of NAFLD compared to previous biomarkers used to estimate the risk of NAFLD in patients with T2D such as liver enzymes (AST, ALT and ALP) and BMI [10]. This evidence concerns the gene GPT and autoimmune pancreatitis.